药明巨诺-B（JW Therapeutics）宣布，其CAR-T细胞疗法Carteyva（relma-cel）作为复发或难治性大B细胞淋巴瘤（R/R LBCL）二线治疗的补充新药申请（sNDA），预计将于2026年获得中国国家药品监督管理局（NMPA）的批准。
这一进展标志着Carteyva在拓展适应症方面取得重要突破。若获批，该疗法将为R/R LBCL患者提供新的治疗选择，进一步巩固药明巨诺在细胞治疗领域的领先地位。
药明巨诺-B（JW Therapeutics）宣布，其CAR-T细胞疗法Carteyva（relma-cel）作为复发或难治性大B细胞淋巴瘤（R/R LBCL）二线治疗的补充新药申请（sNDA），预计将于2026年获得中国国家药品监督管理局（NMPA）的批准。
这一进展标志着Carteyva在拓展适应症方面取得重要突破。若获批，该疗法将为R/R LBCL患者提供新的治疗选择，进一步巩固药明巨诺在细胞治疗领域的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.